muromonab-Cd3 /myo̅o̅′rəmon″ab/ , a parenteral immunosuppressant drug, a monoclonal antibody that interferes with the function of the T cell antigen recognition receptors. ▪ INDICATIONS: It is used to control acute renal transplant rejection, and to control liver or pancreas rejection or graft-versus-host disease when conventional methods are unsuccessful. ▪ CONTRAINDICATIONS: Hypersensitivity to muromonab-CD3 or any other murine products, patients in fluid over or those with greater than 3% weight gain over the past week, uncontrolled hypertension, or uncompensated heart failure. ▪ ADVERSE EFFECTS: It causes a first-dose effect within 1 to 3 hours that ranges from mild flu-like symptoms to a life-threatening anaphylaxis. Pulmonary edema, fever, chills, breathing difficulty, chest pain, vomiting, nausea, diarrhea, and tremors are among the adverse effects associated with each administration.
